The relationship, structure and profiles of schizophrenia measurements: a post-hoc analysis of the baseline measures from a randomized clinical trial

The relationship, structure and profiles of schizophrenia measurements: a post-hoc analysis of the baseline measures from a randomized clinical trial

<p>Background</p> <p>To fully assess the various dimensions affected by schizophrenia, clinical trials often include multiple scales measuring various symptom profiles, cognition, quality of life, subjective well-being, and functional impairment. In this exploratory study, we chara...

Full description

Bibliographic Details
Main Authors:	Chen Lei, Phillips Glenn, Johnston Joseph, Kinon Bruce J, Ascher-Svanum Haya, Kollack-Walker Sara, Succop Paul, Naber Dieter
Format:	Article
Language:	English
Published:	BMC 2011-12-01
Series:	BMC Psychiatry
Online Access:	http://www.biomedcentral.com/1471-244X/11/203

Similar Items

Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia
by: Zhao Zhongyun, et al.
Published: (2005-01-01)

Long-term healthcare costs and functional outcomes associated with lack of remission in schizophrenia: a post-hoc analysis of a prospective observational study
by: Haynes Virginia S, et al.
Published: (2012-12-01)

Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia
by: Nyhuis Allen W, et al.
Published: (2009-09-01)

Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients’ and clinicians’ perspectives in a clinical trial
by: Faries Douglas, et al.
Published: (2012-09-01)

Predictors of switching antipsychotic medications in the treatment of schizophrenia
by: Stauffer Virginia L, et al.
Published: (2010-09-01)

Involvement in the US criminal justice system and cost implications for persons treated for schizophrenia
by: Faries Douglas E, et al.
Published: (2010-01-01)

Cost-effectiveness of early responders versus early nonresponders to atypical antipsychotic therapy
by: Peng X, et al.
Published: (2011-04-01)

Methodological issues in assessing changes in costs pre- and post-medication switch: a schizophrenia study example
by: Nyhuis Allen W, et al.
Published: (2009-05-01)

Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia
by: Xiaomei Peng, et al.
Published: (2011-01-01)

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
by: Correll Christoph, et al.
Published: (2005-05-01)

Change in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychotics
by: Osuntokun Olawale, et al.
Published: (2011-05-01)

Cost of antipsychotic polypharmacy in the treatment of schizophrenia
by: Correll Christoph U, et al.
Published: (2008-04-01)

Medication adherence levels and differential use of mental-health services in the treatment of schizophrenia
by: Furiak Nicolas M, et al.
Published: (2009-01-01)

The Group of Treatment Resistant Schizophrenias. Heterogeneity in Treatment Resistant Schizophrenia (TRS)
by: Bruce J. Kinon
Published: (2019-01-01)

Sustained favorable long-term outcome in the treatment of schizophrenia: a 3-year prospective observational study
by: Ascher-Svanum Haya, et al.
Published: (2011-08-01)

Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy
by: Keefe Richard SE, et al.
Published: (2009-07-01)

The cost of relapse and the predictors of relapse in the treatment of schizophrenia
by: Slade Eric P, et al.
Published: (2010-01-01)

Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health Administration
by: Zhao Yingnan, et al.
Published: (2009-12-01)

Reasons for continuing or discontinuing olanzapine in the treatment of schizophrenia from the perspectives of patients and clinicians
by: Chen J, et al.
Published: (2011-11-01)

Validation of a patient interview for assessing reasons for antipsychotic discontinuation and continuation
by: Matza LS, et al.
Published: (2012-07-01)

Predictors of continuation with olanzapine during the 1-year naturalistic treatment of patients with schizophrenia in Japan
by: Ye W, et al.
Published: (2011-12-01)

Predictors of antipsychotic monotherapy with olanzapine during a 1-year naturalistic study of schizophrenia patients in Japan
by: Ye W, et al.
Published: (2012-01-01)

Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States
by: Smolen Lee J, et al.
Published: (2009-04-01)

Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection
by: Ascher-Svanum H, et al.
Published: (2014-06-01)

Item response analysis of the Positive and Negative Syndrome Scale
by: Lindenmayer Jean-Pierre, et al.
Published: (2007-11-01)

Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons
by: Ascher-Svanum H, et al.
Published: (2012-05-01)

Double-blind, randomized trial comparing efficacy and safety of continuing olanzapine versus switching to quetiapine in overweight or obese patients with schizophrenia or schizoaffective disorder
by: Walter Deberdt, et al.
Published: (2008-09-01)

Providing baselines for biodiversity measurement.
by: Willis, K, et al.
Published: (2005)

Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia
by: Stauffer Virginia L, et al.
Published: (2011-09-01)

Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis
by: Heinloth Alexandra N, et al.
Published: (2009-03-01)

Cure or curse? Ambivalent attitudes towards neuroleptic medication in schizophrenia and non-schizophrenia patients
by: Dieter Naber, et al.
Published: (2009-10-01)

The post hoc measurement as a safe and reliable method to age and size plethodontid salamanders
by: Enrico Lunghi, et al.
Published: (2020-10-01)

Complexity measures in magnetoencephalography: measuring "disorder" in schizophrenia.
by: Matthew J Brookes, et al.
Published: (2015-01-01)

Hospitalisation as an outcome measure in schizophrenia
by: Burns, T
Published: (2007)

Evolution of outcome measures in schizophrenia
by: Burns, T
Published: (2007)

Evaluation of social cognitive measures in an Asian schizophrenia sample
by: Keane Lim, et al.
Published: (2020-06-01)

Baseline Measurements of Waves and Currents along the Coast of Oman
by: Ahmad Sana, et al.
Published: (2023-08-01)

Geodetic and astrometic measurements with very-long-baseline interferometry.
by: Robertson, Douglas Scott
Published: (2010)

Experimental Comparison of Outdoor Baseline Measurements by Different Methods
by: Gu Youyi, et al.
Published: (2019-01-01)

Evaluation of social cognitive measures in an Asian schizophrenia sample
by: Lim, Keane, et al.
Published: (2020)